Testosterone release rate and duration of action of testosterone pellet implants

Clinical Endocrinology

Volumn 60, Issue 4, 2004, Pages 420-428

  Kelleher, S ^a   Howe, C ^a   Conway, A J ^a   Handelsman, D J ^a,b  

^a UNIVERSITY OF SYDNEY   (Australia)

^b ANZAC RESEARCH INSTITUTE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; EXCIPIENT; FOLLITROPIN; LUTEINIZING HORMONE; TESTOSTERONE;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; CRYSTAL; DRUG RELEASE; DRY WEIGHT; HORMONE DEFICIENCY; HORMONE SUBSTITUTION; HUMAN; HYPOGONADISM; IMPLANT; MAJOR CLINICAL STUDY; MALE; PELLET EXTRUSION; PRIORITY JOURNAL; REIMPLANTATION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; DELAYED-ACTION PREPARATIONS; DRUG ADMINISTRATION SCHEDULE; DRUG IMPLANTS; EQUIPMENT FAILURE; HORMONE REPLACEMENT THERAPY; HUMANS; HYPOGONADISM; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RANDOMIZED CONTROLLED TRIALS; REGRESSION ANALYSIS; TESTOSTERONE; TIME FACTORS;

EID: 1842840800     PISSN: 03000664     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2265.2004.01994.x     Document Type: Article

References (50)

1. Amory, J.K., Anawalt, B.D., Blaskovich, P.D., Gilchriest, J., Nuwayser, E.S. & Matsumoto, A.M. (2002) Testosterone release from a subcutaneous, biodegradable microcapsule formulation (Viatrel) in hypogonadal men. Journal of Andrology, 23, 84-91.
2. Bailey, B.J. & Briars, G.L. (1996) Estimating the surface area of the human body. Statistics in Medicine, 15, 1325-1332.
3. Baisley, K.J., Boyce, M.J., Bukofzer, S., Pradhan, R. & Warrington, S.J. (2002) Pharmacokinetics, safety and tolerability of three dosage regimens of buccal adhesive testosterone tablets in healthy men suppressed with leuprorelin. Journal of Endocrinology, 175, 813-819.
4. Bals-Pratsch, M., Knuth, U.A., Yoon, Y.D. & Nieschlag, E. (1986) Transdermal testosterone substitution therapy for male hypogonadism. Lancet, 2, 943-946.
5. Behre, H.M. & Nieschlag, E. (1992) Testosterone buciclate (20 Aet-1) in hypogonadal men: pharmacokinetics and pharmacodynamics of the new long-acting androgen ester. Journal of Clinical Endocrinology and Metabolism, 75, 1204-1210.
6. Behre, H.M. & Nieschlag, E. (1998) Comparative pharmacokinetics of testosterone esters. In: Testosterone: Action Deficiency Substitution, 2nd edn (eds E. Nieschlag & H.M. Behre), pp. 329-348. Springer, Berlin.
7. Behre, H.M., Abshagen, K., Oettel, M., Hubler, D. & Nieschlag, E. (1999) Intramuscular injection of testosterone undecanoate for the treatment of male hypogonadism: phase I studies. European Journal of Endocrinology/European Federation of Endocrine Societies, 140, 414-419.
8. Bhasin, S., Swerdloff, R.S., Steiner, B., Peterson, M.A., Meridores, T., Galmirini, M., Pandian, M.R., Goldberg, R. & Berman, N. (1992) A biodegradable testosterone microcapsule formulation provides uniform eugonadal levels of testosterone for 10-11 weeks in hypogonadal men. Journal of Clinical Endocrinology and Metabolism, 74, 75-83.
9. Buckler, H.M., Kasai, P.K., Cantrill, J.A. & Anderson, D.C. (1995) An audit of oestradiol levels and implant frequency in women undergoing subcutaneous implant therapy. Clinical Endocrinology, 42, 445-450.
10. Burris, A.S., Ewing, L.L. & Sherins, R.J. (1988) Initial trial of slow-release testosterone microspheres in hypogonadal men. Fertility and Sterility, 50, 493-497.
11. Chien, Y.W. (1992) Novel Drug Delivery Systems, 2nd edn. Marcel Dekker, New York.
12. Conway, A.J., Boylan, L.M., Howe, C., Ross, G. & Handelsman, D.J. (1988) A randomised clinical trial of testosterone replacement therapy in hypogonadal men. International Journal of Andrology, 11, 247-264.
13. Deansley, R. & Parkes, A.S. (1938) Further experiments on the administration of hormones by the subcutaneous implantation of tablets. Lancet, ii, 606-608.
14. Dobs, A.S., Hoover, D.R., Chen, M.C. & Allen, R. (1998) Pharmacokinetic characteristics, efficacy, and safety of buccal testosterone in hypogonadal males: a pilot study. Journal of Clinical Endocrinology and Metabolism, 83, 33-39.
15. von Eckardstein, S. & Nieschlag, E. (2002) Treatment of male hypogonadism with testosterone undecanoate injected at extended intervals of 12 weeks: a phase II study. Journal of Andrology, 23, 419-425.
16. Efron, B. & Tibshirani R.J. (1993) An Introduction to the Bootstrap. Chapman & Hall, New York.
17. Garnett, T., Studd, J.W., Henderson, A., Watson, N., Savvas, M. & Leather, A. (1990) Hormone implants and tachyphylaxis. British Journal of Obstetrics and Gynaecology, 97, 917-921.
18. Hamilton, J.B. (1937) Treatment of sexual underdevelopment with synthetic male hormone substance. Endocrinology, 21, 649-654.
19. Handelsman, D.J. (1991) Testosterone Implants: A Manual of Scientific and Clinical Information. Stredder Print, Auckland.
20. Handelsman, D.J. (1998) Clinical pharmacology of testosterone pellet implants. In: Testosterone Action Deficiency Substitution, 2nd edn (eds E. Nieschlag & H.M. Behre), pp. 349-364. Springer, Berlin.
21. Handelsman, D.J. (2001) Androgen action and pharmacologic uses. In: Endocrinology, 4th edn (ed. L.J. DeGroot), pp. 2232-2242. W B Saunders, Philadelphia.
22. Handelsman, D.J., Conway, A.J. & Boylan, L.M. (1990) Pharmacokinetics and pharmacodynamics of testosterone pellets in man. Journal of Clinical Endocrinology and Metabolism, 71, 216-222.
23. Handelsman, D.J., Conway, A.J., Howe, C.J., Turner, L. & Mackey, M.A. (1996) Establishing the minimum effective dose and additive effects of depot progestin in suppression of human spermatogenesis by a testosterone depot. Journal of Clinical Endocrinology and Metabolism, 81, 4113-4121.
24. Handelsman, D.J., Mackey, M.A., Howe, C., Turner, L. & Conway, A.J. (1997) Analysis of testosterone implants for androgen replacement therapy. Clinical Endocrinology, 47, 311-316.
25. Ishak, K.G. & Zimmerman, H.J. (1987) Hepatotoxic effects of the anabolic-androgenic steroids. Seminars in Liver Disease, 7, 230-236.
26. Jockenhovel, F., Vogel, E., Kreutzer, M., Reinhardt, W., Lederbogen, S. & Reinwein, D. (1996) Pharmacokinetics and pharmacodynamics of subcutaneous testosterone implants in hypogonadal men. Clinical Endocrinology, 45, 61-71.
27. Junkman, K. (1957) Long-acting steroids in reproduction. Recent Progress in Hormone Research, 13, 380-419.
28. Kelleher, S., Turner, L., Howe, C., Conway, A.J. & Handelsman, D.J. (1999) Extrusion of testosterone pellets: a randomized controlled clinical study. Clinical Endocrinology, 51, 469-471.
29. Kelleher, S., Conway, A.J. & Handelsman, D.J. (2001) Influence of implantation site and track geometry on the extrusion rate and pharmacology of testosterone implants. Clinical Endocrinology, 55, 531-536.
30. Kelleher, S., Conway, A.J. & Handelsman, D.J. (2002) A randomised controlled clinical trial of antibiotic impregnation of testosterone pellet implants to reduce extrusion rate. European Journal of Endocrinology, 146, 513-518.
31. Lisser, H., Escamilla, R.F. & Curtis, L.E. (1942) Testosterone therapy of male eunuchoids. III. Sublingual administration of testosterone compounds. Journal of Clinical Endocrinology, 2, 351-360.
32. Liu, P.Y., Wishart, S.M. & Handelsman, D.J. (2002) A double-blind, placebo-controlled, randomized clinical trial of recombinant human chorionic gonadotropin on muscle strength and physical function and activity in older men with partial age-related androgen deficiency. Journal of Clinical Endocrinology and Metabolism, 87, 3125-3135.
33. Ly, L.P., Jimenez, M., Zhuang, T.N., Celermajer, D.S., Conway, A.J. & Handelsman, D.J. (2001) A double-blind, placebo-controlled, randomized clinical trial of transdermal dihydrotestosterone gel on muscular strength, mobility, and quality of life in older men with partial androgen deficiency. Journal of Clinical Endocrinology and Metabolism, 86, 4078-4088.
34. McDonald, H.P.B., Garg, A.X.M.D.M.A. & Haynes, R.B.M.D.P. (2002) Interventions to enhance patient adherence to medication prescriptions. Scientific Review. JAMA, 288, 2868-2879.
35. Meikle, A.W., Mazer, N.A., Moellmer, J.F., Stringham, J.D., Tolman, K.G., Sanders, S.W. & Odell W.D. (1992) Enhanced transdermal delivery of testosterone across nonscrotal skin produces physiological concentrations of testosterone and its metabolites in hypogonadal men. Journal of Clinical Endocrinology and Metabolism, 74, 623-628.
36. Nieschlag, E., Mauss, J., Coert, A. & Kicovic, P. (1975) Plasma androgen levels in men after oral administration of testosterone or testosterone undecanoate. Acta Endocrinologica, 79, 366-374.
37. Salehian, B., Wang, C., Alexander, G., Davidson, T., McDonald, V., Berman, N., Dudley, R.E., Ziel, F. & Swerdloff, R.S. (1995) Pharmacokinetics, bioefficacy, and safety of sublingual testosterone cyclodextrin in hypogonadal men: comparison to testosterone enanthate - a clinical research center study. Journal of Clinical Endocrinology and Metabolism, 80, 3567-3575.
38. Snyder, P.J. & Lawrence, D.A. (1980) Treatment of male hypogonadism with testosterone enanthate. Journal of Clinical Endocrinology and Metabolism, 51, 1335-1339.
39. Southren, A.L., Gordon, G.G. & Tochimoto, S. (1968) Further studies of factors affecting metabolic clearance rate of testosterone in man. Journal of Clinical Endocrinology and Metabolism, 28, 1105-1112.
40. Stuenkel, C.A., Dudley, R.E. & Yen, S.S.C. (1991) Sublingual administration of testosterone-hydroxyypropyl-â.cyclodextrin inclusion complex simulates episodic androgen release in hypogonadal men. Journal of Clinical Endocrinology and Metabolism, 72, 1054-1059.
41. Tauber, U., Schroder, K., Dusterberg, B. & Matthes, H. (1986) Absolute bioavailability of testosterone after oral administration of testosterone-undecanoate and testosterone. European Journal of Drug Metabolism and Pharmacokinetics, 11, 145-149.
42. Vierhapper, H., Nowotny, P. & Waldhausl, W. (1997) Determination of testosterone production rates in men and women using stable isotope/dilution and mass spectrometry. Journal of Clinical Endocrinology and Metabolism, 82, 1492-1496.
43. Vierhapper, H., Nowotny, P. & Waldhausl, W. (1998a) Failure of short-term hyperinsulinemia to affect testosterone production rates in healthy men. Metabolism: Clinical and Experiment, 47, 119-120.
44. Vierhapper, H., Nowotny, P. & Waldhausl, W. (1998b) Unchanged testosterone production rates in growth hormone-treated healthy men. Journal of Clinical Endocrinology and Metabolism, 83, 3735-3736.
45. Vierhapper, H., Nowotny, P. & Waldhausl, W. (2000) Production rates of testosterone in patients with Cushing's syndrome. Metabolism: Clinical and Experiment, 49, 229-231.
46. Vierhapper, H., Nowotny, P. & Waldhausl, W. (2003) Reduced production rates of testosterone and dihydrotestosterone in healthy men treated with rosiglitazone. Metabolism: Clinical and Experiment, 52, 230-232.
47. Vlahos, I., MacMahon, W., Sgoutas, D., Bowers, W., Thompson, J. & Trawick, W. (1982) An improved ultrafiltration method for determining free testosterone in serum. Clinical Chemistry, 28, 2286-2291.
48. Wang, C., Eyre, D.R., Clark, R., Kleinberg, D., Newman, C., Iranmanesh, A., Veldhuis, J., Dudley, R.E., Berman, N., Davidson, T., Barstow, T.J., Sinow, R., Alexander, G. & Swerdloff, R.S. (1996) Sublingual testosterone replacement improves muscle mass and strength, decreases bone resorption, and increases bone formation markers in hypogonadal men - a clinical research center study. Journal of Clinical Endocrinology and Metabolism, 81, 3654-3662.
49. Wang, C., Berman, N., Longstreth, J.A., Chuapoco, B., Hull, L., Steiner, B., Faulkner, S., Dudley, R.E. & Swerdloff, R.S. (2000) Pharmacokinetics of transdermal testosterone gel in hypogonadal men: application of gel at one site versus four sites: a General Clinical Research Center Study. Journal of Clinical Endocrinology and Metabolism, 85, 964-969.
50. Zhang, G.Y., Gu, Y.Q., Wang, X.H., Cui, Y.G. & Bremner, W.J. (1998) A pharmacokinetic study of injectable testosterone undecanoate in hypogonadal men. Journal of Andrology, 19, 761-768.